[Advanced medicinal products medical therapy based on mesenchymal stem cells].
作者信息
Renata Szydlak
机构信息
Katedra Biochemii Lekarskiej, Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum, Kraków.
出版信息
Farm Pol. 2018;74(3):178-183.
Abstract
摘要
相似文献
1
[Advanced medicinal products medical therapy based on mesenchymal stem cells].[基于间充质干细胞的先进医药产品医学疗法]
Farm Pol. 2018;74(3):178-183.
2
[Mesenchymal stromal cells in the treatment of graft-versus-host disease: where do we stand?].[间充质基质细胞在移植物抗宿主病治疗中的应用：我们目前的进展如何？]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1265-73. doi: 10.1007/s00103-015-2244-0.
3
GMP-grade human fetal liver-derived mesenchymal stem cells for clinical transplantation.用于临床移植的GMP级人胎儿肝脏来源间充质干细胞。
Methods Mol Biol. 2015;1283:123-36. doi: 10.1007/7651_2014_101.
4
The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.临床血液学家在先进治疗药物新时代中不断扩大的作用。
Br J Haematol. 2017 Jan;176(1):9-15. doi: 10.1111/bjh.14384. Epub 2016 Oct 17.
5
[Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].[先进治疗委员会（CAT）报告。从先进治疗药品的概念到医学治疗过程中的陷阱]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011 Jul;54(7):822-30. doi: 10.1007/s00103-011-1304-3.
6
From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU.在欧盟，从含干细胞的先进治疗药品的发现到获批。
Regen Med. 2016 Jun;11(4):407-20. doi: 10.2217/rme-2015-0051. Epub 2016 Apr 19.
7
Standard operating procedure for the good manufacturing practice-compliant production of human bone marrow mesenchymal stem cells.符合药品生产质量管理规范的人骨髓间充质干细胞生产标准操作规程
Methods Mol Biol. 2015;1283:171-86. doi: 10.1007/7651_2014_103.
8
[Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].[关于高级治疗用医药产品的（欧盟）第1394/2007号法规：纳入国内法]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):14-9. doi: 10.1007/s00103-009-0985-3.
9
[Ethical aspects of human embryonic stem cell use and commercial umbilical cord blood stem cell banking. Ethical reflections on the occasion of the regulation of the European Council and Parliament on advanced therapy medicinal products].[人类胚胎干细胞使用及商业脐带血干细胞库的伦理问题。欧洲理事会和议会关于先进治疗药品监管之际的伦理思考]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):63-7. doi: 10.1007/s00103-009-0994-2.
10
[Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].[关于用于人类和兽用的细胞治疗药物的监管要求——比较]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1299-305. doi: 10.1007/s00103-015-2247-x.
本文引用的文献
1
Mesenchymal Stem Cell-Based Therapy for Kidney Disease: A Review of Clinical Evidence.基于间充质干细胞的肾脏疾病治疗：临床证据综述
Stem Cells Int. 2016;2016:4798639. doi: 10.1155/2016/4798639. Epub 2016 Sep 19.
2
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.欧洲高级治疗用药品（ATMPs）的市场监管监督：欧洲药品管理局/临床试验授权委员会的视角
Adv Exp Med Biol. 2015;871:103-30. doi: 10.1007/978-3-319-18618-4_6.
3
Stem Cell Therapies in Clinical Trials: Progress and Challenges.临床试验中的干细胞疗法：进展与挑战。
Cell Stem Cell. 2015 Jul 2;17(1):11-22. doi: 10.1016/j.stem.2015.06.007.
4
Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use.人用间充质干细胞生产用微生物质量控制标准。
Stem Cells Dev. 2014 May 15;23(10):1074-83. doi: 10.1089/scd.2013.0625. Epub 2014 Feb 20.
5
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.不同良好生产规范工艺下生产的临床级间充质基质细胞在免疫调节特性方面存在差异：免疫质量控制的标准化。
Stem Cells Dev. 2013 Jun 15;22(12):1789-801. doi: 10.1089/scd.2012.0594. Epub 2013 Feb 25.
6
Development of a cell-based medicinal product: regulatory structures in the European Union.基于细胞的药物产品的开发：欧盟的监管结构。
Br Med Bull. 2013;105:85-105. doi: 10.1093/bmb/lds036. Epub 2012 Nov 25.
7
Regulatory considerations in production of a cell therapy medicinal product in Europe to clinical research.在欧洲将细胞治疗药物产品生产转化为临床研究的监管考虑因素。
Clin Exp Med. 2014 Feb;14(1):25-33. doi: 10.1007/s10238-012-0213-6. Epub 2012 Sep 27.
8
Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.人围产组织间充质基质细胞：从基础生物学到细胞治疗。
World J Stem Cells. 2010 Aug 26;2(4):81-92. doi: 10.4252/wjsc.v2.i4.81.
9
In vitro Differentiation Potential of Mesenchymal Stem Cells.间充质干细胞的体外分化潜能
Transfus Med Hemother. 2008;35(3):228-238. doi: 10.1159/000124281. Epub 2008 May 8.
10
[The future of new therapies in clinical medicine].[临床医学中新疗法的未来]
Med Clin (Barc). 2011 Nov 26;137(14):645-9. doi: 10.1016/j.medcli.2010.12.005. Epub 2011 Mar 11.
Zotero 插件